Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

96.64 -0.17 (-0.18%)
Official Closing Price Updated: 4:10 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
30 31 Next >
These 5 Stocks Are Setting Up This Buying Opportunity After Strong Runs
Stocks can offer a new buying opportunity with a pullback to the 50-day line. 
Via Investor's Business Daily
Why Shares of Structure Therapeutics Are Soaring on Friday
The company reported positive results from an early-stage clinical trial for its weight-loss therapy candidate. 
Via The Motley Fool
Newcomer Structure Throws Down The Gauntlet In Obesity Treatment -- Shares Soar 66%
The company is working on a pill to help weight loss, rivaling shots from Novo and, possibly, Lilly. 
Via Investor's Business Daily
Why Is Obesity Focused Structure Therapeutics Stock Trading Higher Today?
Structure Therapeutics Inc (NASDAQ: GPCR) released results from the Phase 1b multiple ascending dose (MAD) study of GSBR-1290 in healthy, overweight, or  
Via Benzinga
Novo Nordisk Targets High Demand Indian Market For Its Popular Obesity Drugs Like Wegovy
Danish pharma giant Novo Nordisk A/s (NYSE: NVO) has set its sights on India for the introduction of its breakthrough  
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $500 Today
Via Benzinga
Is Novo Nordisk a Good Passive Income Stock?
Producing cash isn't a problem for this pharma giant. 
Via The Motley Fool
NYSE:NVO stands out as a growth opportunity that won't break the bank.
NYSE:NVO, a growth stock which is not overvalued. 
Via Chartmill
Don't overlook NYSE:NVO—a stock with solid growth prospects and a reasonable valuation.
In the world of growth stocks, NYSE:NVO shines as a value proposition. 
Via Chartmill
Why Abbott Says It Won't Be A Casualty Of The Weight-Loss Battle
Abbott and Dexcom stocks have tumbled as GLP-1 drugs have gripped the nation. 
Via Investor's Business Daily
3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals
The demand for biotech stocks is intense and is likely to only greatly increase going forward, especially in the United States. 
Via InvestorPlace
Despite Being Costly, Ozempic, Wegovy Prescriptions Surge 300% Over Three Years
An analytics firm Trilliant Health analysis revealed a significant surge in prescriptions for diabetes and obesity drugs like Ozempic and Wegovy during the 
Via Benzinga
Diabetes Prevalence Continues To Rise – Better Therapeutics' Digital Treatment Could Help Change This Trajectory
With the ever-increasing prevalence and staggering economic burden, the demand for innovative solutions to treat diabetes has never been higher 
Via Benzinga
Popular Weight Loss Drugs Ozempic and Wegovy Alert: FDA Adds Intestinal Blockage Warning
In a significant development, the FDA has updated the labeling for Novo Nordisk A/S's (NYSE: NVO) Ozempic, a diabetes drug known for its weight loss side effect, to include warnings about reports of... 
Via Benzinga
Exposures Product Safety
Novo Nordisk Unusual Options Activity For September 21
Via Benzinga
Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds: Today's Top Stories
Benzinga Alibaba's Logistics Arm Cainiao Files For Hong Kong IPO 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Weight Loss Drugs Like Wegovy Could Have Linked Anesthesia Complications, European Medicines Agency To Investigate
The European Medicines Agency (EMA) is set to address concerns related to patients taking drugs such as Novo Nordisk A/S's (NYSE 
Via Benzinga
2 Magnificent Dividend Stocks to Buy Right Now
These two expensive dividend stocks are worth the price of admission. 
Via The Motley Fool
Which High-Profile Stock-Split Stock Is the Cheapest? Get Ready to Be Shocked...
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's one clear-cut stock-split stock that's notably cheaper than the rest. 
Via The Motley Fool
WW International Shares Jump On BCBS Michigan's Revised Authorization For Wegovy, Other Weight Loss Drugs
Via Benzinga
Stock Market Falls Into Correction On Hawkish Fed: Weekly Review
Treasury yields surged to long-term highs, while leading stocks buckled. 
Via Investor's Business Daily
Where Will Novo Nordisk Stock Be in 5 Years?
Weight-loss treatments are a big part of Novo Nordisk's business and could be key to its growth for years to come. 
Via The Motley Fool
Why Novo Nordisk Stock Was Tumbling on Thursday
A downbeat analyst take resonated with investors. 
Via The Motley Fool
Coca-Cola Short Seller Says Dominance Fizzles In Face Of Bubbly Upstarts, Weight Loss Drugs
Coca-Cola short seller says market dominance is fading to competitors and weight-loss drugs such as Ozempic. 
Via Benzinga
FDA Inspection Turns Up 'Objectionable' Bacteria In Key Novo Nordisk Plant
The company says it has since corrected the issues found in the FDA inspection. 
Via Investor's Business Daily
Exposures Product Safety
Why Novo Nordisk Stock Edged Higher Today
The good news outweighed the bad for the hot drug developer on Hump Day. 
Via The Motley Fool
Ypsomed To Supply Autoinjectors To Novo Nordisk Under Long-Term Agreement
Swiss medical technology company Ypsomed (OTC: YPHDF) announced a long-term supply  
Via Benzinga
Eli Lilly Cracks Down on Counterfeit Mounjaro Wight Loss and Diabetes Drugs, Sues Lawsuit Against Clinics
Eli Lilly And Co (NYSE: LLY) has taken  
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Flee to Healthcare Stocks if Recession Rears its Head?
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends. 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Amazon Poaches Microsoft's Product Chief, Google And DoD Team Up For AI-Powered Microscope To Identify Cancer, Rocket Lab's 41st Mission Succumbed To Technical Issues: Today's Top Stories
Bloomberg 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
30 31 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.